FIELD: medicine.
SUBSTANCE: present invention relates to a cobalamin derivative of the formula (I), in which X is ligand with the formula selected from a group consisting of -(CH2)1-5-S-(CH2)0-3-CH3, -S-(CH2)1-5-NH2, 
, where R1 = H, methyl, or ethyl, R2 = 
, and R3 = -H, or 
. A pharmaceutical composition, a food additive, a method for the production of a cobalamin derivative, and its use are also proposed.
EFFECT: proposed cobalamin derivatives of the formula (I) are useful for the treatment of vitamin B12-related disorders caused by either reduced vitamin B12 intake from food to cells that need it, or a genetic defect, or another obstacle in the way of transfer and intracellular recycling of B12.
12 cl, 15 dwg, 6 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COBALAMIN DERIVATIVES USED FOR DIAGNOSIS AND TREATMENT ANOMALOUS CELL PROLIFERATION | 2004 |
|
RU2394042C2 |
| COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING VITAMIN B12 DEFICIENCY | 2017 |
|
RU2730870C2 |
| POLYMER-ASSISTED AMPLIFICATION OF VITAMIN B ABSORPTION SYSTEM | 1994 |
|
RU2139732C1 |
| EXTERNAL COMPOSITIONS CONTAINING ADENOSYL COBALAMIN FOR TREATMENT OF SKIN DISEASES | 2006 |
|
RU2379039C2 |
| ORAL THERAPY OF VITAMIN B DEFICIENCY | 2011 |
|
RU2576511C2 |
| METHOD FOR COMBINED SURGICAL APPLICATION OF FLY LARVAE | 2015 |
|
RU2571062C1 |
| METHOD FOR IDENTIFYING PERSON WITH THE RISK OF NON REVERSIBLE NEUROLOGICAL LESIONS INCLUDING STAGES FOR QUANTITATIVE DETECTION OF PEPSINOGEN I (PG I) AND VITAMIN B 12 CONCENTRATIONS | 2000 |
|
RU2224258C2 |
| COMBINED AGENT BASED ON NSIAD, MUSCLE RELAXANT AND VITAMIN | 2017 |
|
RU2711624C2 |
| ASCORBATE IN PREVENTION OF STATIN-INDUCED VASCULAR CALCIFICATION | 2020 |
|
RU2830123C2 |
| METHOD FOR NORMALIZING METABOLISM IN DOMESTIC ANIMALS | 2003 |
|
RU2266739C2 |
